Amgen (AMGN) Expected to Announce Quarterly Earnings on Thursday

Amgen (NASDAQ:AMGN) is anticipated to issue its Q1 2025 quarterly earnings data after the market closes on Thursday, May 1st. Analysts expect the company to announce earnings of $4.18 per share and revenue of $8.05 billion for the quarter. Amgen has set its FY 2025 guidance at 20.000-21.200 EPS.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, analysts expect Amgen to post $21 EPS for the current fiscal year and $21 EPS for the next fiscal year.

Amgen Price Performance

Amgen stock opened at $283.09 on Tuesday. The business’s 50-day simple moving average is $301.29 and its 200 day simple moving average is $292.11. The stock has a market cap of $152.20 billion, a price-to-earnings ratio of 37.50, a P/E/G ratio of 2.63 and a beta of 0.59. Amgen has a 12-month low of $253.30 and a 12-month high of $346.85. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be issued a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 3.36%. The ex-dividend date of this dividend is Friday, May 16th. Amgen’s dividend payout ratio (DPR) is currently 126.09%.

Insiders Place Their Bets

In other Amgen news, EVP David M. Reese sold 25,225 shares of the business’s stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the transaction, the executive vice president now owns 36,922 shares of the company’s stock, valued at $11,240,533.68. The trade was a 40.59 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Nancy A. Grygiel sold 1,589 shares of the business’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the transaction, the senior vice president now directly owns 7,210 shares in the company, valued at $2,195,228.70. This trade represents a 18.06 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 69,341 shares of company stock valued at $20,644,335 in the last 90 days. 0.69% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Amgen stock. Brighton Jones LLC increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 23.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 27,468 shares of the medical research company’s stock after acquiring an additional 5,226 shares during the quarter. Brighton Jones LLC’s holdings in Amgen were worth $7,159,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Wells Fargo & Company restated an “equal weight” rating on shares of Amgen in a report on Wednesday, February 5th. Citigroup restated a “neutral” rating on shares of Amgen in a report on Wednesday, February 5th. Morgan Stanley raised their target price on Amgen from $328.00 to $330.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 9th. Royal Bank of Canada restated an “outperform” rating and set a $324.00 target price on shares of Amgen in a report on Friday, January 24th. Finally, Truist Financial cut their price objective on Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a report on Wednesday, January 8th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $310.57.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.